CymaBay Focused On PBC With Seladelpar, Wants Partner For NASH

 
• By Joseph Haas
  
scientists doing lab research on digital screen
CymaBay's PBC candidate shows fibrosis, inflammation, liver marker benefits
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D